These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 17638577)

  • 1. Regulation of osteoclast differentiation and function by phosphate: potential role of osteoclasts in the skeletal abnormalities in hypophosphatemic conditions.
    Hayashibara T; Hiraga T; Sugita A; Wang L; Hata K; Ooshima T; Yoneda T
    J Bone Miner Res; 2007 Nov; 22(11):1743-51. PubMed ID: 17638577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
    J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.
    Liu S; Rowe PS; Vierthaler L; Zhou J; Quarles LD
    J Endocrinol; 2007 Jan; 192(1):261-7. PubMed ID: 17210763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.
    Martin A; David V; Laurence JS; Schwarz PM; Lafer EM; Hedge AM; Rowe PS
    Endocrinology; 2008 Apr; 149(4):1757-72. PubMed ID: 18162525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteopontin deficiency suppresses high phosphate load-induced bone loss via specific modulation of osteoclasts.
    Koyama Y; Rittling SR; Tsuji K; Hino K; Salincarnboriboon R; Yano T; Taketani Y; Nifuji A; Denhardt DT; Noda M
    Endocrinology; 2006 Jun; 147(6):3040-9. PubMed ID: 16513836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia.
    Liu S; Brown TA; Zhou J; Xiao ZS; Awad H; Guilak F; Quarles LD
    J Am Soc Nephrol; 2005 Jun; 16(6):1645-53. PubMed ID: 15843468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of bone resorption by inorganic phosphate is mediated by both reduced osteoclast formation and decreased activity of mature osteoclasts.
    Yates AJ; Oreffo RO; Mayor K; Mundy GR
    J Bone Miner Res; 1991 May; 6(5):473-8. PubMed ID: 2068953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the type II Na(+)-Pi cotransporter (Npt2) in the osteoclast and the skeletal phenotype of Npt2-/- mice.
    Gupta A; Tenenhouse HS; Hoag HM; Wang D; Khadeer MA; Namba N; Feng X; Hruska KA
    Bone; 2001 Nov; 29(5):467-76. PubMed ID: 11704500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin regulates osteoclast differentiation through its transporter.
    Battaglino R; Fu J; Späte U; Ersoy U; Joe M; Sedaghat L; Stashenko P
    J Bone Miner Res; 2004 Sep; 19(9):1420-31. PubMed ID: 15312242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disordered osteoclast formation and function in a CD38 (ADP-ribosyl cyclase)-deficient mouse establishes an essential role for CD38 in bone resorption.
    Sun L; Iqbal J; Dolgilevich S; Yuen T; Wu XB; Moonga BS; Adebanjo OA; Bevis PJ; Lund F; Huang CL; Blair HC; Abe E; Zaidi M
    FASEB J; 2003 Mar; 17(3):369-75. PubMed ID: 12631576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of a human homolog of osteoclast inhibitory lectin that inhibits the formation and function of osteoclasts.
    Hu YS; Zhou H; Myers D; Quinn JM; Atkins GJ; Ly C; Gange C; Kartsogiannis V; Elliott J; Kostakis P; Zannettino AC; Cromer B; McKinstry WJ; Findlay DM; Gillespie MT; Ng KW
    J Bone Miner Res; 2004 Jan; 19(1):89-99. PubMed ID: 14753741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss.
    Kim TH; Jung JW; Ha BG; Hong JM; Park EK; Kim HJ; Kim SY
    J Nutr Biochem; 2011 Jan; 22(1):8-15. PubMed ID: 20233653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development.
    Okamoto M; Murai J; Yoshikawa H; Tsumaki N
    J Bone Miner Res; 2006 Jul; 21(7):1022-33. PubMed ID: 16813523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoblasts mediate insulin-like growth factor-I and -II stimulation of osteoclast formation and function.
    Hill PA; Reynolds JJ; Meikle MC
    Endocrinology; 1995 Jan; 136(1):124-31. PubMed ID: 7828521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEPE has the properties of an osteoblastic phosphatonin and minhibin.
    Rowe PS; Kumagai Y; Gutierrez G; Garrett IR; Blacher R; Rosen D; Cundy J; Navvab S; Chen D; Drezner MK; Quarles LD; Mundy GR
    Bone; 2004 Feb; 34(2):303-19. PubMed ID: 14962809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha9beta1: a novel osteoclast integrin that regulates osteoclast formation and function.
    Rao H; Lu G; Kajiya H; Garcia-Palacios V; Kurihara N; Anderson J; Patrene K; Sheppard D; Blair HC; Windle JJ; Choi SJ; Roodman GD
    J Bone Miner Res; 2006 Oct; 21(10):1657-65. PubMed ID: 16995821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
    Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
    Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.